Bookrunners Leerink Partners, Stifel, Nicolaus assist with financing
By Devika Patel
Knoxville, Tenn., Aug. 5 – Zogenix, Inc. said the underwriters for its public sale of stock opted to exercise the deal’s $12.83 million greenshoe in full, lifting total proceeds of the offering to $98.33 million. The deal was announced July 28 and priced for $85.5 million with the greenshoe on July 30.
The company sold 5,462,500 common shares at $18.00 per share. The price per share is a 2.65% discount to the July 29 closing share price of $18.49. Of the shares, 712,500 were part of the fully exercised greenshoe.
Leerink Partners LLC and Stifel, Nicolaus & Co. Inc. were the bookrunners.
Proceeds will be used for clinical research and development, commercial activities, working capital and other general corporate purposes.
San Diego-based Zogenix is a pharmaceutical company focused on medicines to treat central nervous system disorders and pain.
| Issuer: | Zogenix, Inc.
|
| Issue: | Common stock
|
| Amount: | $98,325,000, including $12,825,000 greenshoe of 712,500 shares
|
| Shares: | 5,462,500
|
| Price: | $18.00
|
| Warrants: | No
|
| Bookrunners: | Leerink Partners LLC and Stifel, Nicolaus & Co. Inc.
|
| Co-managers: | Oppenheimer & Co. and Brean Capital, LLC
|
| Announcement date: | July 28
|
| Pricing date: | July 30
|
| Settlement date: | Aug. 5
|
| Stock symbol: | Nasdaq: ZGNX
|
| Stock price: | $18.49 at close July 29
|
| Market capitalization: | $378.22 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
